Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/18634
Title: Hemodynamic Effects of the Non-Peptidic Angiotensin-(1-7) Agonist AVE0991 in Liver Cirrhosis.
Authors: Klein, Sabine;Herath, Chandana B;Schierwagen, Robert;Grace, Josephine;Haltenhof, Tom;Uschner, Frank E;Strassburg, Christian P;Sauerbruch, Tilman;Walther, Thomas;Angus, Peter W;Trebicka, Jonel
Affiliation: Department of Gastronenterology and Hepatology, Austin Health, Heidelberg, Victoria, Australia
Department of Pharmacology and Therapeutics, University College Cork, Cork, Ireland
Department of Obstetrics, Centre for Perinatal Medicine, Division of Women and Child Health, University of Leipzig, Leipzig, Germany
Department of Internal Medicine I, University of Bonn, Bonn, Germany
Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Issue Date: 25-Sep-2015
EDate: 2015
Citation: PloS one 2015; 10(9): e0138732
Abstract: Although in cirrhosis with portal hypertension levels of the vasoconstrictor angiotensin II are increased, this is accompanied by increased production of angiotensin (Ang)-(1-7), the endogenous ligand of the Mas receptor (MasR), which blunts hepatic fibrosis and decreases hepatic vascular resistance. Therefore, we investigated the effects of the non-peptidic Ang-(1-7) agonist, AVE0991, in experimental cirrhosis. Cirrhosis was induced by bile duct ligation (BDL) or carbon tetrachloride (CCl4) intoxication. The coloured microsphere technique assessed portal and systemic hemodynamic effects of AVE0991 in vivo. Hepatic expression of eNOS, p-eNOS, iNOS, JAK2, ROCK and p-Moesin were analyzed by western blots. Activities of ACE and ACE2 were investigated fluorometrically. Moreover, fibrosis was assessed in BDL rats receiving AVE0991. In vivo, AVE0991 decreased portal pressure (PP) in both rat models of cirrhosis. Importantly, systemic effects were not observed. The hepatic effects of AVE0991 were based on upregulation of vasodilating pathways involving p-eNOS and iNOS, as well as by downregulation of the vasoconstrictive pathways (ROCK, p-Moesin). Short-term treatment with AVE0991 decreased the activity of ACE2, long-term treatment did not affect hepatic fibrosis in BDL rats. The non-peptidic agonist of Ang-(1-7), AVE0991, decreases portal pressure without influencing systemic pressure. Thus, although it does not inhibit fibrosis, AVE0991 may represent a promising new therapeutic strategy for lowering portal pressure.
URI: http://ahro.austin.org.au/austinjspui/handle/1/18634
DOI: 10.1371/journal.pone.0138732
PubMed URL: 26406236
Type: Journal Article
Research Support, Non-U.S. Gov't
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.